Literature DB >> 34177424

Ethical Issues and Management of Fetal Hemolytic Anemia Caused by Anti-Rh17 in a Multipara with Rare -D- Phenotype.

Patrick P Torreiter1, Susanne Macher1, Eva-Maria Matzhold1, Bernhard Resch2, Philipp Klaritsch3, Günther F Körmöczi4, Helene Polin5, Leopold Neuhold6, Marlies Schönbacher4, Peter Schlenke1, Thomas Wagner1.   

Abstract

BACKGROUND: The development of allo-anti-Rh17 (anti-Hr0) in a -D- phenotype whose red blood cells (RBCs) lack CcEe antigens is most likely triggered by transfusion, transplantation, or pregnancy. Gene conversion is the predominating factor in generating RHD-CE-D and RHCE-D-CE hybrids like -D-.
METHODS: We report here immunohematological and obstetrical data from 2 of the 5 pregnancies of a 24-year-old woman presenting with the -D- phenotype with anti-Rh17. Blood group typing, antibody screening, antibody differentiation, direct antiglobulin test (DAT), and antibody titers were performed by routine gel technology and tube testing. Additionally, molecular genetic analysis was performed. Fetal surveillance was done by sonographic evaluation of the fetal middle cerebral artery peak systolic velocity (MCA-PSV).
RESULTS: Blood group typing showed O, C-c-D+E-e- and the DAT was negative. DNA sequencing revealed homozygosity for an RHCE-D(3-9)-CE null allele. Anti-Rh17 titers in the fourth pregnancy remained between 1:8 and 1:128, and no signs for a fetal anemia were observed. However, in the fifth pregnancy, the antibody titers increased up to 1:4,096. Signs of moderate fetal anemia were detected and cesarean section was performed at 34 + 6 weeks of gestation. The newborn presented with hemolytic anemia (cord blood hemoglobin [Hb] = 8.5 mg/dL). She received 2 compatible (small) packed RBC concentrates, phototherapy, and intravenous immunoglobulins.
CONCLUSION: Our case shows that the risk for hemolytic complications increases with the number of pregnancies of sensitized women. Only people who also lack CcEe antigens are compatible as donors. The role of such rare donors as lifesavers, their freedom, and voluntariness conflict with the urgent need for compatible blood.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Anti-Rh17 (anti-Hr0); Hemolytic anemia; Hyperbilirubinemia; Maternal alloimmunization; Medical ethics

Year:  2021        PMID: 34177424      PMCID: PMC8216032          DOI: 10.1159/000513124

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  18 in total

1.  Successful management of pregnancy and hemolytic disease of the newborn due to anti-HrO in a woman of the D--phenotype.

Authors:  R Deitenbeck; B Tutschek; G Crombach; H Stannigel
Journal:  Transfusion       Date:  1999-10       Impact factor: 3.157

2.  Anti-Rh17 (anti-Hr0): a rare diagnostic and management problem.

Authors:  N Salamat; F A Bhatti; A Hussain
Journal:  J Pak Med Assoc       Date:  2004-04       Impact factor: 0.781

Review 3.  Adverse events and safety issues in blood donation--a comprehensive review.

Authors:  Karin Amrein; Angelika Valentin; Gerhard Lanzer; Camilla Drexler
Journal:  Blood Rev       Date:  2011-10-11       Impact factor: 8.250

Review 4.  Ethical issues and challenges in implementing a new blood system.

Authors:  M A Somerville
Journal:  Transfus Med Rev       Date:  1998-07

5.  Successful management of fetal hemolytic disease due to strong anti-Rh17 with plasma exchange and intrauterine transfusion in a woman with the D-- phenotype.

Authors:  Kazuya Mimura; Masayuki Endo; Atsushi Takahashi; Yohei Doi; Mikiko Sakuragi; Tomoko Kiyokawa; Hidetoshi Taniguchi; Yasuji Kitabatake; Mika Handa; Takuji Tomimatsu; Yoshiaki Tomiyama; Yoshitaka Isaka; Tadashi Kimura
Journal:  Int J Hematol       Date:  2019-09-19       Impact factor: 2.490

6.  First report of the rare RhCE-depleted D--phenotype in sixteen people of Iranian origin.

Authors:  Ehsan Shahverdi; Mostafa Moghaddam; Hassan Abolghasemi
Journal:  Vox Sang       Date:  2019-02-19       Impact factor: 2.144

7.  Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17.

Authors:  G A Denomme; G Ryan; P G R Seaward; E N Kelly; B J Fernandes
Journal:  Transfusion       Date:  2004-09       Impact factor: 3.157

8.  The RHCE allele ceRT: D epitope 6 expression does not require D-specific amino acids.

Authors:  Franz F Wagner; Birgit Ladewig; Willy A Flegel
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

9.  The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the IronWoMan RCT.

Authors:  Susanne Macher; Cornelia Herster; Magdalena Holter; Martina Moritz; Eva Maria Matzhold; Tatjana Stojakovic; Thomas R Pieber; Peter Schlenke; Camilla Drexler; Karin Amrein
Journal:  Nutrients       Date:  2020-05-05       Impact factor: 5.717

10.  Ethical aspects of blood donors and the recipients of their blood.

Authors:  P J M van den Burg; K Magnussen
Journal:  J Blood Transfus       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.